One crop has seen demand grow by 500% across Europe
23rd May 2019
Since the passing of the Cannabis for Medicinal Use Act, demand for quality, safe medicines has grown by over 500%, and it’s projected to double again.
There is one crop that has seen demand grow more than any other across Europe.
That Crop is Cannabis.
Since the passing of the Cannabis for Medicinal Use Act, demand for quality, safe medicines has grown by over 500%, and it’s projected to double again.
According to the report by Arcview Market Research and BDS Analytics: “The Road Map to a USD57 Billion Worldwide Market” spending on legal cannabis worldwide is expected to hit USD57 billion by 2027.
In Europe specifically, the second edition of the European Cannabis Report (produced by London-based advisory group Prohibition Partners) suggest that with 12% of the continents 739 million people being either “irregular and intensive” cannabis consumers, Europe’s annual medical cannabis market will hit 35.7 billion euros over the next 10 years.
“Medical cannabis” is a broad term for any sort of cannabis-based medicine used to relieve symptoms.
Many cannabis-based products are available to buy online, but their quality and content is not known. They may be illegal and potentially dangerous.
The fastest growing companies are ones who are officially licenced to cultivate and manufacture the crop for medicinal and scientific use.
Eco Equity are one such company. They combine research, development and manufacturing in order to develop products that are safe and affordable for export.
It’s not just pharmaceutical companies that are cashing in.
Suitable investors can also invest in medicinal cannabis either through stocks or directly into companies offering private equity.
To find out how you could invest in medicinal Cannabis, download Eco Equity’s free brochure HERE.
